E6011
E6011 is a pharmaceutical drug with 8 clinical trials. Historical success rate of 85.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
75.0%
6 of 8 finished
25.0%
2 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of E6011 in Participants With Active Crohn's Disease
A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics
A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate
A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
Clinical Trials (8)
A Study of E6011 in Participants With Active Crohn's Disease
A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics
A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate
A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects
A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8